Greg Thomas focuses on improving access to therapies for underserved populations through innovative pediatric formulations at Kiel Laboratories.
2
The Vyscoxa project aimed to create an oral solution for juvenile rheumatoid arthritis, addressing the limitations of existing hard gelatin capsules.
3
Developing oral suspensions for pediatric patients involves challenges like palatability, bioavailability, and stability of the formulation.
4
The use of novel excipients in formulations can enhance product characteristics, but requires extensive safety data for regulatory approval.
5
Future formulation scientists will need skills in digital fluency, data analysis, and collaboration to adapt to complex therapies and regulatory changes.
